Halozyme Therapeutics’ Positive Results for Patients with Chronic Inflammatory Demyelinating Polyneuropathy

The way drugs are being delivered into patients’ bodies have become more than ever considered important with regard to the safety and efficacy of the treatments. We consider Halozyme Biopharmaceutical is a leader in bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients.

Having touched more than 700,000 patient lives in post-marketing use in six . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.